Regulatory Filings • Apr 18, 2014
Regulatory Filings
Open in ViewerOpens in native device viewer
Contracts signed with HTA Co., the leading provider of radiopharmaceuticals in China
Louvain-la-Neuve, Belgium, 18 April, 2014 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy and radiopharmacy solutions, today announces it has signed contracts with HTA Co. Ltd. for the delivery and installation of three cyclotrons Cyclone® 18. A long term agreement was also signed for the maintenance of all IBA cyclotrons installed at HTA. The estimated value of the deal to IBA is approximately EUR 4 million.
Each contract includes the delivery and installation of Cyclone® 18 cyclotron and Synthera® chemistry modules to HTA's new radiopharmaceuticals production centers in China. IBA will also intensively train HTA's experts on the operation of its equipment.
Olivier Legrain, Chief Executive Officer of IBA commented: "These contracts further demonstrate the significant demand for IBA's technology in Asia. We look forward to collaborating with HTA to make Positron Emission Tomography (PET) accessible to more patients in China."
"IBA was selected for its technology and unique know-how in cyclotron development," said Mrs. Liu Qiong, HTA Vice President. "With three new radio-isotopes production centers, HTA continues to rapidly expand its network in China".
HTA Co., Ltd. is the leading provider of radiopharmaceuticals in China with production and distribution centers located throughout China providing radioactive isotope labelled radiopharmaceuticals, such as Molybdenum/Technetium 99 generator, Iodine 131, Strontium 89, Fluorine-18 etc. Such short lived radioisotopes are used extensively in hospital for a.o. use in Gamma camera's PET/CT's and PET/MRI's. With the three new PET drug distribution centers HTA's network will have a total of ten centres in China. HTA will continue to rapidly expand this network system in coming 3-5 years. www.atom-hitech.com
-ENDS-
Press release | 18 April, 2014 1 | 2
IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.
The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.
Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.
IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com
IBA Jean-Marc Bothy Chief Financial Officer Tel: +32 10 47 58 90 [email protected]
Thomas Ralet Vice-President Corporate Communication +32 10 47 58 90 [email protected]
For media and investor enquiries: Consilium Strategic Communications Amber Bielecka, Mary-Jane Elliott, Matthew Neal, Ivar Milligan, Jessica Hodgson +44 (0)20 3709 5700 [email protected]
Press release | 18 April, 2014 2 | 2
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.